10-Q: Protagenic Therapeutics Reports Third Quarter 2024 Financial Results, Cites Ongoing Clinical Trial Progress

Protagenic Therapeutics reported a net loss of $640,785 for the third quarter of 2024, alongside updates on their clinical trial for PT00114 and a recent private placement.

Summary

• Protagenic Therapeutics, a biopharmaceutical company, reported a net loss of $640,785 for the three months ended September 30, 2024, and a net loss of $3,971,601 for the nine months ended September 30, 2024.
• The company's operating loss for the three months ended September 30, 2024 was $652,066, compared to $1,431,712 for the same period in 2023.
• For the nine months ended September 30, 2024, the operating loss was $4,057,772, compared to $3,314,748 for the same period in 2023.
• Research and development expenses were $324,352 for the three months ended September 30, 2024, and $2,981,498 for the nine months ended September 30, 2024.
• General and administrative expenses were $287,882 for the three months ended September 30, 2024, and $1,018,793 for the nine months ended September 30, 2024.
• The company had cash of $1,055,805 and working capital of $633,389 as of September 30, 2024.
• The company anticipates needing additional debt or equity financing by the third quarter of 2025 to continue operations.
• A private placement of 1,948,295 shares of common stock and warrants was completed on November 4, 2024, raising gross proceeds of approximately $1.275 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the progress of clinical trials and the recent capital raise, the company's significant losses, going concern issue, and Nasdaq delisting notice raise serious concerns. The overall sentiment is cautiously negative.

Positives

• The operating loss decreased for the three months ended September 30, 2024, compared to the same period in 2023.
• Research and development expenses decreased for the three months ended September 30, 2024, compared to the same period in 2023.
• The company successfully completed a private placement, raising $1.275 million in gross proceeds.
• The company is actively progressing its Phase I/IIa clinical trial for PT00114.

Negatives

• The company reported a net loss of $640,785 for the third quarter of 2024 and $3,971,601 for the nine months ended September 30, 2024.
• The company's operating loss increased for the nine months ended September 30, 2024, compared to the same period in 2023.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has a going concern issue and will need to raise additional capital by the third quarter of 2025.
• The company received a delisting notice from Nasdaq due to not meeting the minimum bid price requirement.

Risks

• The company has a history of significant recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
• The company needs to secure additional debt or equity financing by the third quarter of 2025 to fund operations.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to misstatements in financial reports.
• The company received a delisting notice from Nasdaq for not meeting the minimum bid price requirement, and there is no guarantee they will regain compliance.
• The company's clinical trials are subject to risks and uncertainties, and there is no guarantee of successful outcomes.

Future Outlook

The company anticipates further losses in the development of its business and will need to obtain debt or equity financing by the third quarter of 2025 to continue operations. The company is also working to regain compliance with Nasdaq listing requirements.

Management Comments

• Management believes that the credit risk with regard to cash deposits is not significant.
• Management has determined its subsidiary's local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary.
• Management intends to implement added controls and procedures to address material weaknesses in internal control over financial reporting.

Industry Context

The company operates in the biopharmaceutical industry, which is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on neuropsychiatric disorders aligns with a growing need for new treatments in this area. The company's financial results and going concern issues are not uncommon for development-stage biopharmaceutical companies.

Comparison to Industry Standards

• Protagenic's financial situation is typical of early-stage biotech companies that are pre-revenue and heavily reliant on external funding.
• Compared to other companies in the biotech sector, Protagenic's R&D spending is relatively low, reflecting its current stage of development.
• The company's reliance on stock-based compensation is a common practice in the biotech industry to attract and retain talent.
• The going concern issue is a significant risk, but not uncommon for companies in this sector that are still in the clinical trial phase.
• The Nasdaq delisting notice is a serious concern, and the company's ability to regain compliance will be critical for its future.

Corporate Governance

Legal Proceedings

• Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against the company that could reasonably be expected to have a material adverse effect on its business and financial condition.

Related Party Transactions

• The company is provided free office space by the Company Executive Chairman, Dr. Armen.
• The company incurred $39,832 in expenses related to research and development services from Agenus Inc. during the three months ended September 30, 2024.
• The company incurred $57,481 in expenses related to research and development services from Agenus Inc. during the nine months ended September 30, 2024.
• The company has an outstanding balance of $39,832 owed to Agenus Inc. as of September 30, 2024.
• The company has an outstanding balance of $80,409 owed to CTC North, GmbH as of September 30, 2024.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and dilution from future capital raises.
• Employees may be concerned about the company's financial stability and future prospects.
• Customers and suppliers may be impacted by the company's ability to continue operations.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company needs to continue its Phase I/IIa clinical trial for PT00114.
• The company needs to secure additional debt or equity financing by the third quarter of 2025.
• The company needs to regain compliance with Nasdaq listing requirements by January 20, 2025.
• The company needs to implement added controls and procedures to address material weaknesses in internal control over financial reporting.

Key Dates

Keywords

biopharmaceutical, clinical trials, neuropsychiatric disorders, PT00114, financial results, going concern, private placement, Nasdaq delisting, research and development, stock warrants